LAMP2A (Lysosomal-Associated Membrane Protein 2A) is the isoform A splice variant of the LAMP2 gene product, serving as the rate-limiting receptor for chaperone-mediated autophagy (CMA). Unlike macroautophagy, which engulfs bulk cytoplasmic material, CMA selectively targets individual proteins bearing a KFERQ-like pentapeptide motif for direct translocation across the lysosomal membrane[1]. LAMP2A is the only known receptor for this pathway: substrate proteins are recognized by cytosolic Hsc70, delivered to LAMP2A on the lysosomal surface, and translocated through a LAMP2A multimer channel into the lysosomal lumen for degradation[2]. CMA dysfunction, driven primarily by age-dependent LAMP2A decline, has emerged as a central mechanism in Parkinson's disease, Alzheimer's disease, and other proteinopathies where failed clearance of pathological proteins drives neuronal death[3][4].
| Attribute | Value |
|---|---|
| Protein Name | Lysosomal-Associated Membrane Protein 2A |
| Gene Symbol | LAMP2 |
| UniProt ID | P13473 (isoform A) |
| Protein Length | 410 amino acids |
| Molecular Weight | ~45 kDa (core), ~120 kDa (glycosylated) |
| Chromosomal Location | Xq24 |
| Subcellular Localization | Lysosomal membrane |
LAMP2A is a type I transmembrane protein with three distinct regions:
The large luminal domain (~350 residues) is heavily glycosylated with N-linked and O-linked glycans, forming a glycan coat that protects the lysosomal membrane from resident hydrolases. This domain is shared with LAMP2B and LAMP2C isoforms and contains a proline-rich hinge region[1:1].
A single transmembrane helix anchors LAMP2A in the lysosomal membrane. This segment is critical for LAMP2A multimerization — substrate translocation requires assembly of LAMP2A monomers into a ~700 kDa translocation complex at the lysosomal surface[2:1].
The 12-amino-acid cytoplasmic tail is unique to the LAMP2A isoform (generated by alternative splicing of exon 9A) and is the functional element that distinguishes LAMP2A from LAMP2B/C. This tail contains four positively charged residues essential for substrate binding and contains the critical Gly-Tyr doublet required for CMA activity. The cytoplasmic tail directly binds Hsc70-substrate complexes, initiating the translocation process[1:2][5].
LAMP2A is the sole receptor and translocation channel for CMA. The pathway operates through a defined sequence[2:2][3:1]:
Key neuronal CMA substrates include:
CMA activity is controlled primarily through LAMP2A protein levels at the lysosomal membrane, not through transcriptional regulation. LAMP2A undergoes constitutive degradation in the lysosomal lumen through cathepsin A-mediated cleavage, and is also cleaved by metalloproteinases in lipid microdomains. During CMA activation (starvation, oxidative stress), LAMP2A degradation slows, increasing receptor density and CMA capacity[5:1].
CMA dysfunction is a major contributor to Parkinson's disease pathogenesis:
In Alzheimer's disease, CMA dysfunction contributes to tau pathology:
Mutant huntingtin fragments with expanded polyglutamine tracts are CMA substrates but, similar to mutant alpha-synuclein, can block the LAMP2A translocation complex. CMA upregulation through LAMP2A overexpression ameliorates huntingtin aggregation in cellular models[3:3].
The most consistent change in CMA across aging and neurodegeneration is the progressive decline in LAMP2A levels at the lysosomal membrane. This decline is driven by changes in lysosomal membrane lipid composition (increased cholesterol content) that accelerate LAMP2A degradation. Genetic restoration of LAMP2A levels in aged mouse liver restores CMA activity and improves proteostasis[5:2][8].
| Strategy | Mechanism | Status |
|---|---|---|
| LAMP2A gene therapy | AAV-mediated LAMP2A overexpression in vulnerable neurons | Preclinical (rat PD models) |
| CMA activators | Small molecules that stabilize LAMP2A at lysosomal membrane | Discovery phase |
| Cholesterol reduction | Statins to normalize lysosomal membrane lipid composition | Epidemiological support |
| AR7 and derivatives | Retinoic acid receptor alpha agonists that transcriptionally upregulate LAMP2A | Preclinical |
| Hsc70 modulators | Enhance substrate delivery to LAMP2A | Early research |
Eskelinen EL. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Molecular Aspects of Medicine. 2006. ↩︎ ↩︎ ↩︎
Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM. The chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane. Molecular and Cellular Biology. 2008. ↩︎ ↩︎ ↩︎
Cuervo AM, Wong E. Chaperone-mediated autophagy: roles in disease and aging. Cell Research. 2014. ↩︎ ↩︎ ↩︎ ↩︎
Xilouri M, Brekk OR, Stefanis L. Autophagy and alpha-synuclein: relevance to Parkinson's disease and related synucleinopathies. Movement Disorders. 2016. ↩︎ ↩︎ ↩︎ ↩︎
Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. Nature Reviews Molecular Cell Biology. 2018. ↩︎ ↩︎ ↩︎
Cuervo AM, Stefanis L, Bhatt DK, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004. ↩︎
Xilouri M, Brekk OR, Landeck N, et al. Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration. Brain. 2013. ↩︎
Zhang C, Bhatt DK. Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nature Medicine. 2008. ↩︎